GlassScriptPhysician profile
Judi L Siebold
NPI 1710307343
$2,949.04
in general payments reported to CMS, 2019-2025
22 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $631 · 2023: $454 · 2024: $1,370 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.50 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.36 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.72 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $308.10 | 2021-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Alkermes, INC. | $267.75 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $152.93 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $137.49 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $114.20 | 2022-2024 | Ingrezza |
| Corium, LLC | $104.84 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $61.79 | 2022-2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $52.88 | 2024 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $47.99 | 2022 | |
| Bausch Health US, LLC | $45.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.62 | 2025 | Cobenfy |
| Orexo US, INC. | $39.85 | 2022-2024 | Zubsolv |
| Boston Scientific Corporation | $32.89 | 2025 | General - Pain Management |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $23.61 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.73 | 2021 | |
| Indivior INC. | $22.13 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $21.51 | 2022 | |
| Owp Pharmaceuticals, INC. | $20.94 | 2023 | Subvenite, Lamotrigine |
| Axsome Therapeutics, INC. | $17.08 | 2023 | Sunosi |
| Almatica Pharma LLC | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judi Siebold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.